RIVA-BISOPROLOL 10 MG
BISOPROLOL FUMARATE : 10 MG · DIN 02471272 · LABORATOIRE RIVA INC.
Health Canada status: CANCELLED POST MARKET
What is RIVA-BISOPROLOL?
RIVA-BISOPROLOL 10 MG contains BISOPROLOL FUMARATE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02471272, held by LABORATOIRE RIVA INC., supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 19-Jul-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RIVA-BISOPROLOL used for?
Management of patients with mild to moderate hypertension. May be used alone or in combination with other antihypertensive agents, particularly thiazide diuretics.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02471272 |
|---|---|
| Brand name | RIVA-BISOPROLOL |
| Generic / active ingredient | BISOPROLOL FUMARATE : 10 MG |
| Manufacturer | LABORATOIRE RIVA INC. |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB07 BISOPROLOL |
| AHFS class | 24:24.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 19-Jul-2022 |
| Original market date | 2018-01-19 00:00:00 |
How is it administered?
Individualized. Usual starting dose: 5 mg once daily. May be increased to 10 mg then 20 mg once daily if response is inadequate. Titration interval: 2 weeks.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text.
How is it supplied?
Not explicitly detailed in the provided text (mentions 5 mg and 10 mg tablets).
Contraindications
Cardiogenic shock, overt heart failure, second or third degree A-V block, right ventricular failure secondary to pulmonary hypertension, and sinus bradycardia.
Warnings and precautions
Avoid in overt heart failure; do not abruptly cease therapy (taper over 2 weeks); caution in peripheral vascular disease, bronchospastic disease, diabetes, and thyrotoxicosis.
What can be used instead?
Other Canadian products sharing ATC code C07AB07 BISOPROLOL. 24 of 52 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-BISOPROLOL | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02521164 |
| AG-BISOPROLOL | 5 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02521156 |
| APO-BISOPROLOL | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02256177 |
| APO-BISOPROLOL | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02256134 |
| BISOPROLOL | 10 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02391597 |
| BISOPROLOL | 5 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02391589 |
| BISOPROLOL TABLETS | 10 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02495570 |
| BISOPROLOL TABLETS | 5 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02495562 |
| JAMP BISOPROLOL | 10 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02518791 |
| JAMP BISOPROLOL | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02518805 |
Who else supplies BISOPROLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. BISOPROLOL appears in 699 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.